Content area
Full text
Hopkinton, Mass.-based Aderis Pharmaceuticals Inc. has filed for a $100 million IPO. The company, which just days ago changed its name from Discovery Therapeutics Inc., develops small molecule drugs to treat diseases of the central nervous system as well as cardiovascular and renal disorders. One of its main products is Rotigotine, a transdermal patch which treats Parkinson's disease. Net proceeds from the IPO will be used for research and development, acquisition of new technologies or products, working capital and general corporate purposes. The underwriters are UBS Warburg llc, CIBC World Markets Corp. and Dain Rauscher Inc. Among the key investors in Aderis are: The Palladin Group, a Maplewood, N.J.-based life sciences investment firm; Schroder Ventures International Life Sciences; Perseus-Soros Biopharmaceutical Fund LP of San Diego; and Sanderling BioMedical Ventures of Menlo Park, Calif. The issuer's law firm is Los Angeles-based Latham & Watkins. Shares of Aderis will trade on the Nasdaq under the symbol ADPX. www.TheDeal.com